Refine by
Quantum Blue Medical Equipment & Supplies In In Lithuania
6 equipment items found
Manufactured by:BÜHLMANN Laboratories AG based inSchönenbuch, SWITZERLAND
The Quantum Blue® Adalimumab assay measures from 1.3 to 35 µg/ml. The target concentrations for the optimal therapeutic window lies well within the linear range of the test. Quantum Blue® Adalimumab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately while following up the patient’s ...
Manufactured by:BÜHLMANN Laboratories AG based inSchönenbuch, SWITZERLAND
The Quantum Blue® Infliximab assay measures from 0.4 to 20 µg/mL. The target concentrations for trough level interpretation lies well within the linear range of the test. Quantum Blue® Infliximab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately before infusion of the next infliximab dose. ...
Manufactured by:BUHLMANN Diagnostics Corp based inAmherst, NEW HAMPSHIRE (USA)
BÜHLMANN MRP8/14 ELISA and Quantum Blue® MRP8/14 are for Research Use Only. Not for use in diagnostic procedures in the US. MRP8/14 Assays (myeloid-related protein) (aka serum calprotectin, sCAL, ...
Manufactured by:BUHLMANN Diagnostics Corp based inAmherst, NEW HAMPSHIRE (USA)
The Quantum Blue® Calprotectin lateral flow assay combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody to calprotectin), with full quantification by means of a small, telephone sized reading device. The Quantum Blue® Reader analyzes the signal intensity from the test and control line to give a quantitative value and is standardized with the ...
Manufactured by:BÜHLMANN Laboratories AG based inSchönenbuch, SWITZERLAND
Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of anti TNFα biologics has been a significant step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Adalimumab is the first anti TNFα biologic on the market approved for patient self-administration by ...
Manufactured by:BÜHLMANN Laboratories AG based inSchönenbuch, SWITZERLAND
Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNFα biologics like infliximab has been a significant step forward to ameliorating disease course and keeping inflammations at remission levels for prolonged periods of time. Patients with too low drug concentrations have worse outcomes than those with adequate drug levels. ...